ClinicalTrials.gg
CompletedNCT03026855Updated Jan 20, 2017

Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers

A Phase 1 interventional study of Autologous PRP Gel and PRP Injection in Chronic Ulcer, sponsored by TotipotentRX Cell Therapy Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-01-20.

Sponsored by TotipotentRX Cell Therapy Pvt. Ltd. · Phase 1, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 11 studies in Ulcer with a site in India — 2 open to participants now, 2 under way, 2 of them phase 3. Ulcer · India.

Enrollment
9th of 11
24 · median 70
Started
2014
the only one that year
Phase 1
3 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
TotipotentRX Cell Therapy Pvt. Ltd.

Among the 11 studies in Ulcer with a site in India, this one is the 9th largest by enrollment, is the only one that started in 2014, is one of 3 in phase 1, and was the 7th registered.

Ulcer

359 studies on the registry are indexed under Ulcer; 60 are open to participants now.

Browse Ulcer studies →

Open to participants now

2 of the 11 studies in Ulcer with a site in India are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 39 Ulcer studies recruiting now, 30 (77%) set no upper age limit and 3 (8%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ulcer with a site in India, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of autologous PRP injection in combination with topical application of PRP gel in treating chronic or non-healing ulcers on lower extremity using a rapid, intra-operative, point-of-care technology at the patient's bedside.

Read the detailed description

Platelet Rich Plasma (PRP) therapy is an innovative treatment that uses body's own cells to relieve pain and promote accelerated healing of Non-healing Foot Ulcer /Wound. The body's response to any tissue injury is to deliver platelets, which play an instrumental role in the normal healing process by secreting growth factors and attracting stem cells-critical components of the healing cascade.

Any wound or ulcer on skin that has been present for 4-5 weeks duration, without healing is called a non-healing ulcer. Non-healing ulcers include venous, arterial, diabetic, pressure and traumatic ulcers. Cellular therapies using Autologous Platelet Rich Plasma provides new options for wound healing. The efficacy of the treatment has been proven in surgical applications, in the treatment of severe burns and in transplantation of cells and tissues.

Local application of a solution of plasma enriched in platelets derived from the patient's blood intends to trigger the healing process in non-responsive chronic wound, increase the wound repair rate and reduce pain. PRP is a good option for non-healing wounds because it utilizes the body's natural healing processes to jump-start wound healing. Plasma which contains very valuable growth factors is separated from other blood components utilizing a point of care technology based on density gradient centrifugation. The platelet rich plasma is harvested and then activated by a mixture of human thrombin and calcium chloride for initiating the healing cascade followed by PRP injection directly into the ulcer/wound periphery or spread over a wound in the form of a PRP gel.

03

Conditions studied

  • Chronic Ulcer

Browse trials for

Keywords

  • Autologous PRP
  • Non-healing ulcer
  • Point-of-care
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or Female 18 to 85 years of age
  • Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old
  • Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)
  • Wound area (length x width) measurement must be between 0.5 cm\^2 and 10 cm\^2, inclusive
  • If more than one non-healing ulcers is present, the largest wound will be selected
  • Index ulcer must be clinically non-infected
  • Full-thickness ulcer without exposure of bone, muscle, ligament or tendon
  • Written must be obtained from either the patient or the patients legally acceptable representative prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))
  • Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months
  • count \< 105 x 10\^3/ uL (according to CBC)
  • level \< 10 g/dL (according to CBC)
  • Wound is clinically infected
  • Presence of platelet dysfunction syndrome or critical thrombocytopenia
  • Bleeding disorders, collagen vascular disease or severe cardiovascular disorder
  • Any other than non-melanoma skin cancer
  • Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment
  • If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study
  • Subject has inadequate venous access for blood draw required for PRP preparation
  • Any chronic condition requiring the use of systemic 30 days prior to study entry and anytime during the course of the study
  • Subject is on dialysis or has uncontrolled sugar levels
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Autologous PRP Gel and PRP Injection

    Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.

    Biological: Autologous PRP Gel and PRP Injection

Interventions

  • BiologicalAutologous PRP Gel and PRP Injection

    Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer. Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound. Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment.

06

What researchers measure

Primary outcomes

  1. Number of Wound/ Ulcers Healed

    The number of wound/ ulcers healed will be assessed by visual inspection of reduction in wound size at 24 weeks post PRP therapy

    Time frame: 24 weeks

Secondary outcomes

  1. Time to Ulcer Healing

    The average time taken for the ulcers to heal post PRP administration

    Time frame: 24 weeks

  2. Reduction in Pain using VAS pain score

    Improvement in Pain and discomfort following PRP therapy

    Time frame: 24 weeks

  3. Changes in Quality of Life using the SF-36 Questionnaire

    Improvement in Quality of Life of the patients following PRP therapy

    Time frame: 24 weeks

  4. Number of participants with treatment-related Adverse Events

    Safety of the treatment will be assessed by measuring the number of treatment related adverse events and adverse reactions during the follow-up period

    Time frame: 24 weeks

07

Study locations

1 site
  • Fortis Escorts Heart Institute and Research Centre
    Delhi, 110025, India
08

References and documents

Publications

  • Suthar M, Gupta S, Bukhari S, Ponemone V. Treatment of chronic non-healing ulcers using autologous platelet rich plasma: a case series. J Biomed Sci. 2017 Feb 27;24(1):16. doi: 10.1186/s12929-017-0324-1. PubMed 28241824 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Apr 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2017
First posted
Jan 20, 2017
Start
Jun 2014
Primary completionActual
Apr 2016
CompletionActual
May 2016
Last update
Jan 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03026855
Lead sponsor
TotipotentRX Cell Therapy Pvt. Ltd.
Responsible party
Sponsor
First posted
Jan 20, 2017
Start date
Jun 2014
Primary completion
Apr 2016
Completion
May 2016
Last update
Jan 20, 2017

Study contacts

Dr. Suhail N Bukhari, MBBS, DNB
principal investigator · Fortis Escorts Heart Institute and Research Centre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion